CD209 and neoplasm: Indeed, DCs acquire an immunosuppressive phenotype (CD14+/CD16+/CD68+/CD124+/CD209+; PD-L1 overexpression), becoming incapable of cross-presenting tumor antigens to T cells and inhibiting the T cell response [97].